PPMI Completed & Ongoing Biologic Analyses
Principal InvestigatorOrganizationProject TitleData AvailabilityAnalyteMatrixIncluded Enrollment CohortsSubcategories includedVisit(s)Project IDNotes
 Collaboration powered by Smartsheet   |   Report Abuse
1Peggy Taylor, PhDBioLegendaSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​Currently available
total aSyn, hemoglobin, & total protein
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months102, 103, 111, 124PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1
2Jessie Ni, PhDBioLegendPilot and Large-Scale Study for ASYN in PPMI CSFBridging study available
total aSyn, hemoglobin, & total protein
CSFHealthy Control
Parkinson Disease
Bridging Study in 100 previously evaluated samples201
3Les Shaw, PhDUPennA-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche ElecsysCurrently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months110, 125Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1
4Les Shaw, PhDUPennPPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019Currently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months15975 Bridging study & 2,000+ remaining PPMI samples not yet analyzed from previous efforts
5Clemens Scherzer, MDHarvardEvaluation of PD-linked Transcripts in PPMICurrently available
aSyn transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
Baseline105
6Judith Potashkin, PhDRosalind & Franklin UniversityWhole Blood RNA Biomarkers of PDCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
Baseline114
7Martin Rabey, MDBioShai Ltd.Validation of a Blood-based Gene Expression Assay for Early Diagnosis & Monitoring DiseaseCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline, 12, 24, 36 months119
8Kendall Van Keuren-Jensen, PhDTGen FoundationRNAseq in PPMICurrently available (summary files, raw data for cloud transfer, & data explorer)​
mRNA& miRNA sequencing​
RNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaselilne, 6, 12, 24, 36 months131, 133Data available as summary files, raw data for cloud transfer, & data explorer
9Matthew Farrer, PhDUniversity of BCClinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic VariabilityCurrently available
SNCA genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
Baseline115
10Travis Dunckley, PhD; Paula Desplats, PhDArizona State University; UCSDComprehensive Methylation Profiling of the PPMI Cohort​Currently available
Methylation profiling​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsBaseline, 12, 24, 36 months140
11Sulev Koks, MD, PhDMurdoch UniversityAssociation of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI CohortCurrently available
Tandem repeats
DNAHealthy Control
Parkinson Disease
Baseline160
12Kimberly Billingsley, PhDNIHIdentifying the Role of Structural Variants in PDExpected Q3 2021
Structural variants
DNAHealthy Control
Parkinson Disease
Various179
13Christos Proukakis, MD, PhDUniversity College LondonDetection of GBA Mutations by Combination of Illumina & Nanopore Sequencing​Expected Q4 2021
Long read GBA sequencing
DNAParkinson Disease
Prodromal
GBA subjectsVarious195
14Dwight German, PhDUT SouthwesternBlood biomarker for PDCurrently available
PD2 peptoid
SerumHealthy Control
Parkinson Disease
Baseline123
15Maria Teresa Pellecchia, PhDUniversity of SalernoInsulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PDCurrently available
IGF-1
SerumHealthy Control
Parkinson Disease
Baseline113
16Danielle Graham, PhD; Brit Mollenhauer, MDBiogen; Paracelsus Elena KlinikInvestigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​Currently available
Neurofilament Light (NFL)​
SerumHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsPD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months144
17George Tofaris, MD, PhDUniversity of OxfordSerum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PDSample shipment pending
Neuronal exosomes (aSyn)​
SerumParkinson Disease
Prodromal
GBA & LRRK2 subjectsBaseline204
18Peter Lewitt, MDHenry Ford Health SystemPolyamine Biomarkers of Parkinson Disease ProgressionSample shipment pending
Metabolomics
CSF
Serum
Healthy Control
Parkinson Disease
Baseline, 24 months189
19Alice Chen-Plotkin, MD, MScUPennPlasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s DiseaseCurrently available
ApoA1 & EGF​
PlasmaHealthy Control
Parkinson Disease
Baseline, 6, 12 months112
20Shawn Ritchie, PhDMed-Life DiscoveriesValidation of Plasmalogen Augmentation as a Viable Drug Target in PD​Currently available
Plasmalogen​
PlasmaHealthy Control
Parkinson Disease
SWEDD (legacy)
Genetic subjectsBaseline182
21Pablo Sardi, PhDSanofiGBA-Related Biomarkers in Parkinson's DiseaseCurrently available
GCase activity & sphingolipids​
CSF
Plasma
Whole blood
Healthy Control
Parkinson Disease
SWEDD (legacy)
Baseline, 12, 24, 36 months132, 135
22Jennifer Van Eyk, PhDCedars-SinaiPost-Translational Modification & Protein Quantification of Plasma & CSFExpected Q4 2021
Unbiased proteomics (DIA MS, AMP PD)
CSF
Plasma
Healthy Control
Parkinson Disease
Baseline & 3 longitudinal timepoints177
23Eline Appelmans, PhDFNIHTargeted Proteomics in AMP PDCurrently available
Targeted proteomics (O-Link Explore 1536, AMP PD)​
CSF
Plasma
Healthy Control
Parkinson Disease
Baseline & 3 longitudinal timepoints196
24Marion Buckwalter, PhDStanfordAdaptive Immune Markers for Predicting Cognitive Decline in PDExpected Q3 2021
Immune profiling
CSF
Plasma
Healthy Control
Parkinson Disease
Baseline, 48 months181
25Michael Schwarzschild, PhDMGH & DenaliMetabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PDExpected Q4 2022
Metabolomics
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPlasma: Baseline,12, 24 months; CSF: Baseline only180
26Gavin Hudson, PhDNewcastle UniversityThe Role of Cell-Free Mitochondrial DNA in Neurodegenerative DiseaseCurrently available
Cell-free mitochondrial DNA
CSFHealthy Control
Parkinson Disease
Baseline, 36 months130
27Thomas Kremer, PhD; Kristen Taylor, PhDRocheCSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​Currently available
Catecholamines​
CSFHealthy Control
Parkinson Disease
Baseline, 12, 24 months122
28Richard Batrla-Utermann, PhDRocheRoche NeuroTool KitCurrently available
Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​
CSFHealthy Control
Parkinson Disease
Baseline, 6, 12, 24, 36, 48 months152
29Fiona Elwood, PhDNovartisIdentification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​Currently available
SomaLogic collaboration (with Merck & Novartis)​
CSFHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsBaseline151
30Liana Rosenthal, MDJohn HopkinsIs Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​Expected Q3 2022
Poly ADP-ribose​
CSFHealthy Control
Parkinson Disease
Baseline, 6, 12, 18, 24, 36,48, 60 months165
31Claudio Soto, PhDAmprionMonitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA AssayPhase 1 Currently available; Phase 2 expected Q4
aSyn seeding (PMCA)- Round Robin & Phase 2​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsPhase 1: BL, 36, mo; Phase 2: PD, HC, SWEDD at BL, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at BL and NMC at BL & all visits for phenoconverted155Phase 1 (Baseline & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY
32Roland Heym, PhDAbbvieEvaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s DiseaseCurrently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline, 36 months173
33Byron Caughey, PhDNIHaSyn Seeding Assay Round Robin- NIH​Currently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline, 36 months172
34Kirsten Taylor, PhDRocheaSyn PMCA Assay at AmprionCurrently available
aSyn seeding​ (PMCA in leftover samples)
CSFHealthy Control
Parkinson Disease
Baseline, 12, 24 months176
35Kalpana Merchant, PhDTransTheraDo Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?Currently available
BMP
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months145
36Sebastian Virreira Winter, PhDOmicEra​Targeted & Untargeted MS Based Proteomics of Urine in PDExpected Q4 2021
Urine proteomics
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months190
37Eleanor Coffey, PhDTurku Centre for Biotechnology​PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD"Expected Q4 2021
Protein handling
PBMCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjects3 longitudinal timepoints170
38Diana Matheoud, PhDUniversité de MontréalMitochondria Autoreactivity in PD Patients as a New Biomarker for the DiseaseSample shipment pending
Mitochondrial autoreactivity​
PBMCsHealthy Control
Parkinson Disease
54, 96 months178
39Satpal Virdee, PhD,University of Dundee​Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical ProbesCurrently available
PINK1
FibroblastsHealthy Control
Parkinson Disease
n/a127
40Marlene Jacobson, PhDUniversity of Dundee​Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PDCurrently available
Lysosomal rescue​
FibroblastsHealthy Control
Parkinson Disease
n/a158
41Alejandro Pezzulo, MDUniversity of IowaMultidisciplinary Analysis of Metabolic Dysregulation in Parkinson's DiseaseExpected Q2 2022
Metabolic profiling
FibroblastsHealthy Control
Parkinson Disease
n/a194
42Xinnan Wang, PhDStanford University​Miro, a Biomarker for Parkinson’s DiseaseFibroblast data available; iPSCs expected Q2 2021
Miro
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a129
43Charleen Chu, MD, PhDUniversity of Pittsburgh​ER Stress & Mitochondrial Homeostasis in Parkinson’s DiseaseExpected Q3 2021
ER stress
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
LRRK2 subjectsn/a128
44Lalitha Madhavan, PhDUniversity of Arizona​Development of a Biomarker Platform for Parkinson’s disease Using Patient-derived CellsExpected Q1 2022
Cellular phenotype biomarkers
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
n/a175
45Nilima Prakash, PhDHamm-Lippstadt University of Applied Sciences​Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or ProgressionExpected Q2 2022
Calcium activity
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
n/a136
46Rachit Bakshi, PhDMGH/MIND​Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA NeuronsCurrently available
Urate & Nrf2​
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsn/a137
47Andy Singleton, PhDNIAThe Foundational Data InitiativeCurrently available; interactive portal currently under development, expected Q3 2021
Transcriptional activity, gene regulation, epigenetics​
iPSCsHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsn/a150Data portal under development
48Mark Cookson, PhD​NIALRRK2 Genetic Risk Variants in PDExpected Q2 2021
LRRK2 functional variants​
iPSCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a139
49Nic Dzamko, PhDUniversity of Sydney​Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell linesCurrently available
Inflammation/​lysosomal function
iPSCsHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsn/a141
50Aaron Day WilliamsFlagship 60​Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCsExpected Q3 2021
Phenotyping
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsn/a156
51Matt LaVoie, PhDBrigham & Women’s, Harvard​Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn MetabolismExpected Q3 2022
LRRK2 at lysosomes
iPSCsParkinson DiseaseGBA subjectsn/a149
52Dimitri Krainc, MDNorthwestern UniversityConvergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s DiseaseExpected Q3 2021
GCase activity in dopaminergic neurons​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a148
53Dong-Gyu Jo, PhDSungkyunkwan University​Study for the Propagation of aSyn (Screening the Propagation Relative Genes)Expected Q3 2021
aSyn propagation
iPSCsHealthy Control
Parkinson Disease
GBA & LRRK2 subjectsn/a174
54Ellen Sidransky, MD​NIHDevelopment of Novel TRPML1 Activator for Treatment of PDExpected Q4 2021
Calcium channel agonists
iPSCsHealthy Control
Parkinson Disease
n/a154
55Magdalene Moran, PhDCaraway Therapeutics​Developing TMEM175 Activators as Therapeutics for PDExpected Q1 2022
TMEM175 activators​
iPSCsParkinson DiseaseGBA subjectsn/a199
56Maximiliano Gutierrez, PhDFrancis Crick Institute​The Role of LRRK2 Kinase Activity in Human Macrophage FunctionExpected Q2 2022
LRRK2 kinase activity
iPSCsParkinson DiseaseLRRK2 subjectsn/a161
57Antony Cooper, PhDGarvan Institute​Phenotypic Confirmation of a Potential New Genetic Subtype of Parkinson’s DiseaseExpected Q3 2022
Genetic subtyping
iPSCsHealthy Control
Parkinson Disease
n/a188
58Robert Krencik, PhDHouston Methodist Research Institute​Midbrain Asteroids to Interrogate Human Astrocyte Function within Neural NetworksExpected Q3 2022
Intracellular comms & astrocyte reactivity​
iPSCsHealthy Control
Parkinson Disease
GBA subjectsn/a168
59Claudio Soto, PhDUniversity of Texas​A Novel Model of Parkinson’s Disease in Lab-generated Mini-brainsExpected Q1 2023
Characterization of midbrain organoids​
iPSCsHealthy Control
Parkinson Disease
LRRK2 & SNCA subjectsn/a166
60Erika Holzbaur, PhDUPenn​Investigating Mitochondrial Trafficking Deficits Across PD ModelsExpected Q1 2023
Mitochondrial trafficking​
iPSCsHealthy ControlGenetic subjectsn/a198
61Thomas Schwarz, PhDBoston Children’s Hospital​Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells10HC, 3 SNCA, 1 LRRK2, 2 PD lines available; Remaining expected Q1 2023​
Mitochondrial transport​
iPSCsHealthy Control
Parkinson Disease
Genetic subjectsn/a153
62Emmanouil Metzakopian, PhDUniversity of Cambridge ​High-throughput Single Cell Unbiased Lipidomics Assay in Human iPSC-derived​Expected Q3 2023
Lipidomics​
iPSCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a183
63Deniz Kirik, MD, PhDUniversity of Sydney​Circuitry and Brain-body InteractionsExpected Q1 2024
Circuitry*​
iPSCsParkinson Disease
Prodromal
LRRK2 & SNCA subjectsn/a193
64Xiqun Chen, MD, PhDMass General Hospital​From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s DiseaseExpected Q2 2024
Inflammation*
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a197
65Daphne Koller, PhD​InsitroInsitro PPMI Cell Line ApplicationExpected Q2 2023
2D dopaminergic neuronal culture phenotyping​
iPSCsHealthy Control
Parkinson Disease
GBA & LRRK2 subjectsn/a187
66Manoj Pandey, PhDCincinnati Children’s Hospital​Setting up the Translational Value of Complement 5a Induction of Brain Inflammation & Neuronal Loss in Human Patients w/ Parkinson’s DiseaseExpected Q2 2023
Neuroinflammation
iPSCsHealthy Control
Parkinson Disease
GBA subjectsn/a167
67Kiroaki Kaku, PhDWestern Michigan University​The Role of FAIM in Parkinson’s Disease​Expected Q4 2022
FAIM
iPSCsParkinson DiseaseGBA & SNCA subjectsn/a206
68Adam Mamais, PhDUniversity of Florida​Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial FunctionSample shipment pending
Iron & mitochondrial homeostasis​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a202
69Andrew Singleton, PhDNIASelected Genetic Variants Genotyped Using NeuroX ArrayCurrently available
NeuroX genotyping
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline106/107
70Andrew Singleton, PhDNIAGBA SequencingCurrently available
GBA sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline126
71Andrew Singleton, PhDNIAImmunochip Genotyping on DNA Samples from PPMICurrently available
Immunochip genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline108
72Andrew Singleton, PhDNIAExome Sequencing of PPMI samplesCurrently available
Whole exome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline116
73Andrew Singleton, PhDNIAWhole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​Currently available
Whole genome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline118
74Andrew Singleton, PhDNIAAPOE4 Genotyping​Currently available
APOE4 genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline104
75Dena Hernandez, PhDNIA​DNA Methylation in PPMICurrently available
DNA methylation
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
Baseline120
76Cornelis Blauwendraat, PhDNIALong read DNA sequencing of the PPMI cohort​Expected Q4 2021
Long read DNA sequencing​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline171
77Rebecca Selzer, PhDFUJIFILM Cellular Dynamics, Inc.Production and Commercialization of Differentiated Cell TypesExpected Q3 2022
Dopaminergic neurons
iPSCsHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsn/a218Differentiation into commercially available dopaminergic neurons
78Anumantha Kanthasamy, PhDIowa State UniversityPPMI a-Syn Skin Seeding AssayExpected Q3 2021
aSyn seeding​ (RT-QuIC)- Round Robin
SkinHealthy Control
Parkinson Disease
Baseline211
79Karen MacLeod, Claudio Soto, PhDAmprionDevelopment and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical LaboratoryExpected Q4 2021
aSyn seeding (PMCA)
CSFHealthy Control
Parkinson Disease
Various207Used warmed CSF from various visits